ESG Viewpoint: Diversity in clinical trials Â
Despite a clear scientific and commercial imperative, a significant gap between patient and trial populations persists. We explain why diversity in clinical trials matters to investors and explore our engagement with companies.
COP28 – main takeaways and key outcomes
A last-minute deal on transitioning away from fossil fuels was agreed – but will commitments be implemented? We assess this and other progress made at the 28th round of climate change negotiations in Dubai.
Global Sustainable Outcomes Q3 2023
As interest rates rise, global financial and economic risks also rise, with the renewable sector experiencing a ‘black swan’ event in 2023.
Greater clarity and a focus on financial outcomes
What’s in store for responsible investing from here?
What we expect from COP28 in Dubai
With the 28th round of climate change negotiations looming, we outline some of the main discussion points and consider what progress could be made.
Investing to improve, engaging for impact
Discover the latest impact report for the CT SDG Engagement Global Equity Strategy – covering engagement, multi-year progress, and updates on key Strategy themes.
Sustainable Development Goals: A framework for investors
In 2023, we have reached the halfway point – and a coordinated effort is needed to get the goals on track ahead of 2030.
Chopping and changes: what are the implications of the EU’s Deforestation Regulation?
The EU’s Deforestation Regulation will make us as investors think about company risks and opportunities and is under discussion with our equity and fixed income teams.
ESG Viewpoint: Taiwan’s AGMs
Taiwan’s hybrid AGMs open up to foreign investors but concerns about shareholder rights remain
Thematic Insight: Managing the Human Capital Transition
Human capital, although often overlooked by investors, is a significant component of the forces driving performance. Businesses investing in human capital are likely to derive a competitive advantage.
